Edition:
United Kingdom

Aimmune Therapeutics Inc (AIMT.OQ)

AIMT.OQ on NASDAQ Stock Exchange Global Select Market

22.90USD
18 Jan 2019
Change (% chg)

$0.29 (+1.28%)
Prev Close
$22.61
Open
$22.61
Day's High
$22.96
Day's Low
$21.87
Volume
276,489
Avg. Vol
216,628
52-wk High
$41.75
52-wk Low
$21.38

Latest Key Developments (Source: Significant Developments)

Aimmune Therapeutics Says As A Result Of U.S. Govt Shutdown, Other, FDA Will Not Commence Review Of Co's Bla For Ar101
Monday, 14 Jan 2019 

Jan 14 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS - NOTIFIED BY FDA AS A RESULT OF U.S. GOVERNMENT SHUTDOWN, OTHER, FDA WILL NOT COMMENCE REVIEW OF CO'S BLA FOR AR101.AIMMUNE THERAPEUTICS INC - FDA INDICATED IT WILL INITIATE REVIEW OF BLA WHEN THE U.S. GOVERNMENT SHUTDOWN AND LAPSE IN APPROPRIATIONS HAS ENDED.  Full Article

Aimmune Therapeutics Inc - Announced Exclusive Supply Agreement For Egg Protein With Michael Foods
Thursday, 20 Dec 2018 

Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS ANNOUNCES IND FILING FOR AR201 FOR EGG ALLERGY AND EXCLUSIVE SUPPLY AGREEMENT WITH MICHAEL FOODS.AIMMUNE THERAPEUTICS INC - AR201 FOR EGG ALLERGY PHASE 2 INITIATION PLANNED FOR 2019.AIMMUNE THERAPEUTICS INC - ANNOUNCED EXCLUSIVE SUPPLY AGREEMENT FOR EGG PROTEIN WITH MICHAEL FOODS.  Full Article

Aimmune Therapeutics Announces Closing Of $98 Mln Investment By Nestlé Health Science
Wednesday, 28 Nov 2018 

Nov 28 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS ANNOUNCES CLOSING OF $98 MILLION INVESTMENT BY NESTLÉ HEALTH SCIENCE.AIMMUNE THERAPEUTICS - NESTLÉ HEALTH SCIENCE PURCHASED 3.2 MILLION NEWLY ISSUED CO'S SHARES AT $30.27/SHARE.AIMMUNE THERAPEUTICS INC - SALE OF SHARES WAS MADE PURSUANT TO TERMS OF SECURITIES PURCHASE AGREEMENT ENTERED INTO ON NOVEMBER 11.  Full Article

Aimmune Therapeutics Inc QTRLY Loss Per Share $0.91
Wednesday, 8 Aug 2018 

Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS.AIMMUNE THERAPEUTICS INC QTRLY LOSS PER SHARE $0.91.AIMMUNE THERAPEUTICS INC - CASH, CASH EQUIVALENTS, AND INVESTMENTS TOTALED $295.9 MILLION AT JUNE 30, 2018.  Full Article

Aimmune Extends Supply Agreement With Golden Peanut And Tree Nuts For Experimental Allergy Treatment
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Aimmune Therapeutics Inc ::AIMMUNE THERAPEUTICS BROADENS AND EXTENDS SUPPLY AGREEMENT WITH GOLDEN PEANUT AND TREE NUTS FOR AR101 FOR PEANUT ALLERGY.AIMMUNE THERAPEUTICS INC - ‍NEWLY EXPANDED GLOBAL AGREEMENT SECURES EXCLUSIVE SUPPLY RELATIONSHIP THROUGH 2033​.AIMMUNE THERAPEUTICS INC - AR101 IS CURRENTLY IN PHASE 3 CLINICAL TRIALS, WITH PIVOTAL TOPLINE DATA EXPECTED IN FEBRUARY.AIMMUNE THERAPEUTICS INC - ‍AS PART OF AGREEMENT, AIMMUNE HAS GRANTED ADM A 300,000-SHARE EQUITY STAKE IN AIMMUNE​.AIMMUNE THERAPEUTICS BROADENS AND EXTENDS SUPPLY AGREEMENT WITH GOLDEN PEANUT AND TREE NUTS FOR AR101 FOR PEANUT ALLERGY.AIMMUNE THERAPEUTICS - ‍ AGREEMENT GIVES CO EXCLUSIVE ACCESS TO ADDITIONAL GOLDEN PRODUCTS THAT COULD BE DEVELOPED INTO PEANUT ORAL IMMUNOTHERAPIES​.  Full Article

Aimmune Therapeutics says ‍CEO Stephen Dilly plans to retire by end of 2018​
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Aimmune Therapeutics Inc :Aimmune Therapeutics Inc announces third quarter 2017 financial results and planned retirement of CEO by the end of 2018.Aimmune Therapeutics Inc - ‍CEO Stephen Dilly plans to retire by end of 2018​.Aimmune Therapeutics Inc - ‍Aimmune will initiate a search for a successor CEO​.Aimmune Therapeutics Inc - ‍Dilly will continue as Aimmune's CEO until his replacement joins company and will be available through a transition period​.Aimmune Therapeutics Inc qtrly ‍on a per share basis, net loss for quarter was $0.63​.Q3 earnings per share view $-0.72 -- Thomson Reuters I/B/E/S.Aimmune Therapeutics Inc - ‍expects last double-blind, placebo-controlled food challenge in phase 3 palisade trial of ar101 will be conducted in Dec. 2017​.Aimmune Therapeutics Inc - ‍cash, cash equivalents, and investments were $212.0 million at Sept 30, 2017, compared to $282.5 million at december 31, 2016​.Aimmune Therapeutics Inc - ‍top-line data from phase 3 palisade trial of ar101 will be available in q1 of 2018​.  Full Article

Hundreds of FDA staff return to work amid shutdown -Commissioner

Jan 15 About 400 U.S. Food and Drug Administration staffers have returned to their posts from furlough, including some food inspectors and support professionals, Commissioner Scott Gottlieb said in a tweet on Tuesday.